ADVERTISEMENT
The World Needs the Not-for-Profit AstraZeneca Vaccine, Minus the AstraZeneca Drama
A series of unforced errors by the British pharma company has turned hope into hesitancy.
10 Apr 2021, 12:45 PM IST
(Bloomberg Businessweek) -- Mene Pangalos, head of biopharmaceuticals research for AstraZeneca Plc, went to bed on Monday, March 22, feeling good for the first time in a while. After working around the clock through the weekend, he’d just announced better-than-expected interim results from the company’s large U.S. vaccine trial: The shot was safe and 79% effective at preventing cases of symptomatic Covid-19. Positive news, at last, ...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Minimal Ad
Experience
Members-Only
Rewards
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT